- Home
- ATEX vs ATXS Comparison
ATEX vs ATXS Comparison
Compare ATEX & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- ATXS
- Stock Information
- Founded
- ATEX 1997
- ATXS 2008
- Country
- ATEX United States
- ATXS United States
- Employees
- ATEX N/A
- ATXS N/A
- Industry
- ATEX Telecommunications Equipment
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- ATXS Health Care
- Exchange
- ATEX Nasdaq
- ATXS Nasdaq
- Market Cap
- ATEX 408.7M
- ATXS 401.2M
- IPO Year
- ATEX N/A
- ATXS 2015
- Fundamental
- Price
- ATEX $21.13
- ATXS $6.28
- Analyst Decision
- ATEX Buy
- ATXS Buy
- Analyst Count
- ATEX 2
- ATXS 6
- Target Price
- ATEX $64.00
- ATXS $32.00
- AVG Volume (30 Days)
- ATEX 174.1K
- ATXS 200.3K
- Earning Date
- ATEX 08-12-2025
- ATXS 08-19-2025
- Dividend Yield
- ATEX N/A
- ATXS N/A
- EPS Growth
- ATEX N/A
- ATXS N/A
- EPS
- ATEX N/A
- ATXS N/A
- Revenue
- ATEX $6,031,000.00
- ATXS N/A
- Revenue This Year
- ATEX $5.17
- ATXS N/A
- Revenue Next Year
- ATEX $2.92
- ATXS N/A
- P/E Ratio
- ATEX N/A
- ATXS N/A
- Revenue Growth
- ATEX 43.90
- ATXS N/A
- 52 Week Low
- ATEX $20.61
- ATXS $3.56
- 52 Week High
- ATEX $42.91
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- ATEX 30.74
- ATXS 47.13
- Support Level
- ATEX $21.73
- ATXS $6.47
- Resistance Level
- ATEX $22.26
- ATXS $7.21
- Average True Range (ATR)
- ATEX 0.83
- ATXS 0.40
- MACD
- ATEX 0.10
- ATXS -0.05
- Stochastic Oscillator
- ATEX 22.18
- ATXS 7.02
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.